Corcept Therapeutics Inc (CORT)
50.07
+2.45
(+5.14%)
USD |
NASDAQ |
Nov 04, 16:00
50.07
0.00 (0.00%)
After-Hours: 20:00
Corcept Therapeutics Net Income (Quarterly): 47.21M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 47.21M |
| June 30, 2024 | 35.49M |
| March 31, 2024 | 27.76M |
| December 31, 2023 | 31.36M |
| September 30, 2023 | 31.38M |
| June 30, 2023 | 27.53M |
| March 31, 2023 | 15.88M |
| December 31, 2022 | 16.60M |
| September 30, 2022 | 34.61M |
| June 30, 2022 | 27.41M |
| March 31, 2022 | 22.80M |
| December 31, 2021 | 32.05M |
| September 30, 2021 | 30.47M |
| June 30, 2021 | 26.52M |
| March 31, 2021 | 23.46M |
| December 31, 2020 | 25.99M |
| September 30, 2020 | 21.62M |
| June 30, 2020 | 28.33M |
| March 31, 2020 | 30.06M |
| December 31, 2019 | 29.38M |
| September 30, 2019 | 26.34M |
| June 30, 2019 | 20.19M |
| March 31, 2019 | 18.27M |
| December 31, 2018 | 22.01M |
| September 30, 2018 | 17.75M |
| Date | Value |
|---|---|
| June 30, 2018 | 18.20M |
| March 31, 2018 | 17.46M |
| December 31, 2017 | 98.33M |
| September 30, 2017 | 13.76M |
| June 30, 2017 | 12.65M |
| March 31, 2017 | 4.388M |
| December 31, 2016 | 4.597M |
| September 30, 2016 | 2.585M |
| June 30, 2016 | 0.977M |
| March 31, 2016 | -0.019M |
| December 31, 2015 | 0.959M |
| September 30, 2015 | -0.601M |
| June 30, 2015 | -1.936M |
| March 31, 2015 | -4.83M |
| December 31, 2014 | -3.895M |
| September 30, 2014 | -6.006M |
| June 30, 2014 | -7.552M |
| March 31, 2014 | -13.93M |
| December 31, 2013 | -11.12M |
| September 30, 2013 | -10.91M |
| June 30, 2013 | -11.90M |
| March 31, 2013 | -12.08M |
| December 31, 2012 | -11.12M |
| September 30, 2012 | -8.293M |
| June 30, 2012 | -7.597M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
15.88M
Minimum
Mar 2023
47.21M
Maximum
Sep 2024
28.30M
Average
28.04M
Median
Net Income (Quarterly) Benchmarks
| ADMA Biologics Inc | 32.06M |
| Akebia Therapeutics Inc | -8.582M |
| Bioventus Inc | -23.99M |
| Alnylam Pharmaceuticals Inc | -111.57M |
| Catalyst Pharmaceuticals Inc | 40.79M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 182.55M |
| Total Expenses (Quarterly) | 135.95M |
| EPS Diluted (Quarterly) | 0.41 |
| Enterprise Value | 4.609B |
| Gross Profit Margin (Quarterly) | 98.43% |
| Profit Margin (Quarterly) | 25.86% |
| Earnings Yield | 2.52% |
| Operating Earnings Yield | 2.57% |
| Normalized Earnings Yield | 2.516 |